Giovanni Capranico

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6562860/publications.pdf

Version: 2024-02-01

110	4,812	76326	106344
papers	citations	40	65
		h-index	g-index

114	114	114	5799
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	DNA damage and genome instability by G-quadruplex ligands are mediated by R loops in human cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 816-825.	7.1	217
2	Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1992, 1132, 43-48.	2.4	214
3	In hepatocellular carcinoma miRâ€519d is upâ€regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. Journal of Pathology, 2012, 227, 275-285.	4.5	180
4	Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Research, 1990, 18, 6611-6619.	14.5	179
5	Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry, 1990, 29, 562-569.	2.5	154
6	Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives. International Journal of Molecular Sciences, 2018, 19, 3480.	4.1	153
7	Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. Nucleic Acids Research, 1991, 19, 5973-5980.	14.5	136
8	Anthracyclines: Selected New Developments. Anti-Cancer Agents in Medicinal Chemistry, 2001, 1, 113-130.	7.0	133
9	DNA Topoisomerase I differentially modulates R-loops across the human genome. Genome Biology, 2018, 19, 100.	8.8	114
10	Molecular modelling studies, synthesis and biological activity of a series of novel bisnaphthalimides and their development as new DNA topoisomerase II inhibitors. Bioorganic and Medicinal Chemistry, 2009, 17, 13-24.	3.0	111
11	Dual Processing of R-Loops and Topoisomerase I Induces Transcription-Dependent DNA Double-Strand Breaks. Cell Reports, 2019, 28, 3167-3181.e6.	6.4	108
12	DNA topoisomerase I inhibition by camptothecin induces escape of RNA polymerase II from promoter-proximal pause site, antisense transcription and histone acetylation at the human HIF-1Î± gene locus. Nucleic Acids Research, 2010, 38, 159-171.	14.5	100
13	DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1998, 1400, 185-194.	2.4	98
14	Type I DNA Topoisomerases. Journal of Medicinal Chemistry, 2017, 60, 2169-2192.	6.4	98
15	New developments in antitumor anthracyclines. , 1997, 76, 117-124.		97
16	Characterization of novel antisense HIF-1Î± transcripts in human cancers. Cell Cycle, 2011, 10, 3189-3197.	2.6	92
17	Natural Product Triptolide Mediates Cancer Cell Death by Triggering CDK7-Dependent Degradation of RNA Polymerase II. Cancer Research, 2012, 72, 5363-5373.	0.9	92
18	G-quadruplexâ€“R-loop interactions and the mechanism of anticancer G-quadruplex binders. Nucleic Acids Research, 2020, 48, 11942-11957.	14.5	81

#	Article	IF	Citations
19	DNA-PK triggers histone ubiquitination and signaling in response to DNA double-strand breaks produced during the repair of transcription-blocking topoisomerase I lesions. Nucleic Acids Research, 2016, 44, 1161-1178.	14.5	75
20	Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugs. Journal of Molecular Biology, 1991, 222, 909-924.	4.2	70
21	Relationship between Lethal Effects and Topoisomerase II-Mediated Double-Stranded DNA Breaks Produced by Anthracyclines with Different Sequence Specificity. Molecular Pharmacology, 1997, 51, 1053-1059.	2.3	70
22	DNA topoisomerase-trapping antitumour drugs. European Journal of Cancer, 1992, 28, 2055-2060.	2.8	65
23	Conformational Drug Determinants of the Sequence Specificity of Drug-stimulated Topoisomerase II DNA Cleavage. Journal of Molecular Biology, 1994, 235, 1218-1230.	4.2	65
24	The Natural Inhibitor of DNA Topoisomerase I, Camptothecin, Modulates HIF-1Î± Activity by Changing miR Expression Patterns in Human Cancer Cells. Molecular Cancer Therapeutics, 2014, 13, 239-248.	4.1	63
25	A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons. Trends in Pharmacological Sciences, 1997, 18, 323-329.	8.7	61
26	RNA G-Quadruplexes in Kirsten Ras (KRAS) Oncogene as Targets for Small Molecules Inhibiting Translation. Journal of Medicinal Chemistry, 2017, 60, 9448-9461.	6.4	61
27	Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1995, 1264, 337-346.	2.4	59
28	Doxorubicin Disaccharide Analogue: Apoptosis-Related Improvement of Efficacy In Vivo. Journal of the National Cancer Institute, 1997, 89, 1217-1223.	6.3	58
29	Topoisomerase Poisoning Activity of Novel Disaccharide Anthracyclines. Molecular Pharmacology, 1999, 56, 77-84.	2.3	58
30	Antisense transcripts enhanced by camptothecin at divergent CpG-island promoters associated with bursts of topoisomerase I-DNA cleavage complex and R-loop formation. Nucleic Acids Research, 2013, 41, 10110-10123.	14.5	57
31	Nucleosome positioning as a critical determinant for the DNA cleavage sites of mammalian DNA topoisomerase in reconstituted Simian virus 40 chromatin. Nucleic Acids Research, 1990, 18, 4553-4559.	14.5	56
32	Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II. Biochemistry, 1993, 32, 3038-3046.	2.5	55
33	Design, Synthesis, and Biological Evaluation of Substituted Naphthalene Imides and Diimides as Anticancer Agent. Journal of Medicinal Chemistry, 2009, 52, 7873-7877.	6.4	55
34	Mechanism of action of DNA topoisomerase inhibitors. Stem Cells, 1995, 13, 369-379.	3.2	53
35	Naphthoquinone Derivatives Exert Their Antitrypanosomal Activity via a Multi-Target Mechanism. PLoS Neglected Tropical Diseases, 2013, 7, e2012.	3.0	52
36	Early Effects of Topoisomerase I Inhibition on RNA Polymerase II Along Transcribed Genes in Human Cells. Journal of Molecular Biology, 2006, 357, 127-138.	4.2	51

#	Article	IF	Citations
37	Toward the Development of Specific G-Quadruplex Binders: Synthesis, Biophysical, and Biological Studies of New Hydrazone Derivatives. Journal of Medicinal Chemistry, 2016, 59, 5706-5720.	6.4	51
38	A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons. Trends in Pharmacological Sciences, 1997, 18, 323-329.	8.7	48
39	Comparison of dna cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase ii inhibitors. International Journal of Cancer, 1990, 45, 347-352.	5.1	45
40	The effects of camptothecin on RNA polymerase II transcription: Roles of DNA topoisomerase I. Biochimie, 2007, 89, 482-489.	2.6	44
41	Peptidyl Anthraquinones as Potential Antineoplastic Drugs:â€‰ Synthesis, DNA Binding, Redox Cycling, and Biological Activity. Journal of Medicinal Chemistry, 1996, 39, 3114-3122.	6.4	41
42	DNA Topoisomerase II Structures and Anthracycline Activity: Insights into Ternary Complex Formation. Current Pharmaceutical Design, 2007, 13, 2766-2780.	1.9	41
43	Dynamic Effects of Topoisomerase I Inhibition on R-Loops and Short Transcripts at Active Promoters. PLoS ONE, 2016, 11, e0147053.	2.5	41
44	Comparison of doxorubicin-induced DNA damage in doxorubicin-sensitive and -resistant P388 murine leukemia cells. International Journal of Cancer, 1986, 37, 227-231.	5.1	40
45	Interaction Model for Anthracycline Activity against DNA Topoisomerase IIâ€. Biochemistry, 2004, 43, 7503-7513.	2.5	39
46	Novel Symmetric and Asymmetric DNA Scission Determinants for Streptococcus pneumoniae Topoisomerase IV and Gyrase Are Clustered at the DNA Breakage Site. Journal of Biological Chemistry, 2005, 280, 14252-14263.	3.4	39
47	MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: Alterations in cellular pharmacokinetics and in pattern of cross-resistance. International Journal of Cancer, 1995, 62, 84-89.	5.1	37
48	Base sequence determinants of amonafide stimulation of topoisomerase II DNA clevage. Nucleic Acids Research, 1995, 23, 223-229.	14.5	37
49	Position-Specific Effects of Base Mismatch on Mammalian Topoisomerase II DNA Cleaving Activityâ€. Biochemistry, 1996, 35, 153-159.	2.5	35
50	Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharides. Biochemical Pharmacology, 1999, 57, 1133-1139.	4.4	34
51	Global Transcription Regulation by DNA Topoisomerase I in Exponentially Growing Saccharomyces cerevisiae Cells: Activation of Telomere-Proximal Genes by TOP1 Deletion. Journal of Molecular Biology, 2008, 377, 311-322.	4.2	34
52	The role of topoisomerase II in drug resistance. Life Sciences, 1991, 48, 2195-2205.	4.3	33
53	Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms Î± and Î². Biochemical Pharmacology, 1996, 52, 1675-1685.	4.4	29
54	Novel DNA Topoisomerase IIÎ± Inhibitors from Combined Ligand- and Structure-Based Virtual Screening. PLoS ONE, 2014, 9, e114904.	2.5	28

#	Article	IF	Citations
55	Base mutation analysis of topoisomerase II-idarubicin-DNA ternary complex formation. Evidence for enzyme subunit cooperativity in DNA cleavage. Nucleic Acids Research, 1994, 22, 2274-2281.	14.5	27
56	Dissecting the transcriptional functions of human DNA topoisomerase I by selective inhibitors: Implications for physiological and therapeutic modulation of enzyme activity. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 240-250.	7.4	27
57	Monohydrazone Based G-Quadruplex Selective Ligands Induce DNA Damage and Genome Instability in Human Cancer Cells. Journal of Medicinal Chemistry, 2020, 63, 3090-3103.	6.4	27
58	Mapping Drug Interactions at the Covalent Topoisomerase II-DNA Complex by Bisantrene/Amsacrine Congeners. Journal of Biological Chemistry, 1998, 273, 12732-12739.	3.4	26
59	G1 cell-cycle arrest and apoptosis by histone deacetylase inhibition in MLL-AF9 acute myeloid leukemia cells is p21 dependent and MLL-AF9 independent. Leukemia, 2006, 20, 1307-1310.	7.2	26
60	Cyclohexa-2,5-diene-1,4-dione-based antiproliferative agents: design, synthesis, and cytotoxic evaluation. Journal of Experimental and Clinical Cancer Research, 2013, 32, 24.	8.6	26
61	G-quadruplex binders as cytostatic modulators of innate immune genes in cancer cells. Nucleic Acids Research, 2021, 49, 6673-6686.	14.5	26
62	The topoisomerase II poison clerocidin alkylates non-paired guanines of DNA: implications for irreversible stimulation of DNA cleavage. Nucleic Acids Research, 2001, 29, 4224-4230.	14.5	25
63	Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anti-Cancer Drugs, 1994, 5, 645-649.	1.4	24
64	Development of DNA Topoisomerase-Related Therapeutics: A Short Perspective of New Challenges. Anti-Cancer Agents in Medicinal Chemistry, 2004, 4, 335-345.	7.0	24
65	Discovery of the first dual G-triplex/G-quadruplex stabilizing compound: a new opportunity in the targeting of G-rich DNA structures?. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1271-1280.	2.4	23
66	Effects of base mutations on topoisomerase II DNA cleavage stimulated by mAMSA in short DNA oligomers. Biochemistry, 1993, 32, 145-152.	2.5	22
67	Formation, resealing and persistence of DNA breaks produced by 4-demethoxydaunorubicin in P388 leukemia cells. Chemico-Biological Interactions, 1989, 72, 113-123.	4.0	20
68	Gene expression of DNA topoisomerases I, IIÎ± and IIÎ² and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. , 1996, 67, 479-484.		19
69	Specific Histone Patterns and Acetylase/Deacetylase Activity at the Breakpoint-Cluster Region of the Human MLL Gene. Cancer Research, 2004, 64, 2656-2662.	0.9	19
70	Genomic sites of topoisomerase II activity determined by comparing DNA breakage enhanced by three distinct poisons 1 1Edited by J. Karn. Journal of Molecular Biology, 1999, 285, 545-554.	4.2	17
71	A comparative study of cellular and molecular pharmacology of doxorubicin and MEN 10755, a disaccharide analogue11Abbreviations: DOX, doxorubicin; DNA-SSB, single-strand breaks; and DNA-DSB, double-strand breaks.. Biochemical Pharmacology, 2001, 62, 63-70.	4.4	17
72	Effects of Common Buffer Systems on Drug Activity:â€‰ The Case of Clerocidin. Chemical Research in Toxicology, 2004, 17, 492-501.	3.3	17

#	Article	IF	Citations
73	Metallothionein cDNA cloning, metallothionein expression and heavy metals in Scapharca inaequivalvis along the Northern Adriatic coast of Italy. Ecotoxicology and Environmental Safety, 2011, 74, 366-372.	6.0	17
74	Antitumor AZA-anthrapyrazoles: biophysical and biochemical studies on 8- and 9-aza regioisomers. Biochemical Pharmacology, 2004, 67, 631-642.	4.4	16
75	Characterization of a Topoisomerase II Gene Rearrangement in a Human Small-Cell Lung Cancer Cell Line. Journal of the National Cancer Institute, 1992, 84, 1710-1716.	6.3	15
76	Physicochemical properties, cytotoxic activity and topoisomerase ii inhibition of 2,3-diaza-anthracenediones. Biochemical Pharmacology, 1997, 53, 161-169.	4.4	14
77	Electron Paramagnetic Resonance (EPR) Study of Spin-Labeled Camptothecin Derivatives: A Different Look of the Ternary Complex. Journal of Medicinal Chemistry, 2011, 54, 1003-1009.	6.4	14
78	P-glycoprotein gene amplification and expression in multidrug-resistant murine P388 and B16 cell lines. British Journal of Cancer, 1989, 59, 682-685.	6.4	13
79	DNA-Binding Preferences of Bisantrene Analogues: Relevance to the Sequence Specificity of Drug-Mediated Topoisomerase II Poisoning. Molecular Pharmacology, 1998, 54, 1036-1045.	2.3	13
80	Directed evolution to increase camptothecin sensitivity of human DNA topoisomerase I. Chemistry and Biology, 2001, 8, 871-881.	6.0	13
81	A Novel 9-Aza-Anthrapyrazole Effective against Human Prostatic Carcinoma Xenografts. Oncology, 2001, 61, 234-242.	1.9	12
82	Role of Flexibility in Protein-DNA-Drug Recognition: The Case of Asp677Gly-Val703Ile Topoisomerase Mutant Hypersensitive to Camptothecin. Journal of Amino Acids, 2012, 2012, 1-8.	5.8	12
83	Doxorubicin cellular pharmacokinetics and DNA breakage in a multi-drug resistant B16 melanoma cell line. British Journal of Cancer, 1988, 57, 142-146.	6.4	11
84	Synthesis and Evaluation of New Naphthalene and Naphthoquinone Derivatives as Anticancer Agents. Archiv Der Pharmazie, 2017, 350, e1600286.	4.1	11
85	Lack of effect of glutathione depletion on cytotoxicity, mutagenicity and DNA damage produced by doxorubicin in cultured cells. Chemico-Biological Interactions, 1986, 57, 189-201.	4.0	10
86	Intracellular Distribution of β-Catenin in Human Medulloblastoma Cell Lines with Different Degree of Neuronal Differentiation. Ultrastructural Pathology, 2007, 31, 33-44.	0.9	9
87	Relationships among tumor responsiveness, cell sensitivity, doxorubicin cellular pharmacokinetics and drug-induced DNA alterations in two human small-cell lung cancer xenografts. International Journal of Cancer, 1990, 46, 669-674.	5.1	8
88	A study of cross-resistance pattern and expression of molecular markers of multidrug resistance in a human small-cell lung-cancer cell line selected with doxorubicin. International Journal of Cancer, 1993, 54, 309-314.	5.1	8
89	Synthesis, DNA-damaging and cytotoxic properties of novel topoisomerase II-directed bisantrene analogues. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 121-126.	2.2	8
90	A specific transcriptional response of yeast cells to camptothecin dependent on the Swi4 and Mbp1 factors. European Journal of Pharmacology, 2009, 603, 29-36.	3.5	8

#	Article	IF	Citations
91	Novel Ametantroneâ€“Amsacrine Related Hybrids as Topoisomerase IIÎ² Poisons and Cytotoxic Agents. Archiv Der Pharmazie, 2014, 347, 728-737.	4.1	8
92	Conformational properties of topoisomerase II inhibitors and sequence specificity of DNA cleavage. Journal of Molecular Recognition, 1994, 7, 227-231.	2.1	7
93	Mapping DNA Breaks by Next-Generation Sequencing. Methods in Molecular Biology, 2018, 1672, 155-166.	0.9	6
94	Loss of drug-stimulated topoisomerase II DNA breaks in living cells is different at two unrelated loci. Nucleic Acids Research, 2000, 28, 3289-3293.	14.5	5
95	DROPA: DRIP-seq optimized peak annotator. BMC Bioinformatics, 2019, 20, 414.	2.6	5
96	Enhanced CPT Sensitivity of Yeast Cells and Selective Relaxation of Gal4 Motif-containing DNA by Novel Gal4â€“Topoisomerase I Fusion Proteins. Journal of Molecular Biology, 2004, 337, 295-305.	4.2	4
97	A Rational Selection of Drug Targets Needs Deeper Insights into General Regulation Mechanisms. Anti-Cancer Agents in Medicinal Chemistry, 2004, 4, 393-394.	7.0	3
98	Sequence-Selective Groove Binders. , 1997, , 195-214.		3
99	Further insight into the Zn2+-mediated binding of streptonigrin to DNA. Il Farmaco, 1998, 53, 645-649.	0.9	2
100	10th Conference on DNA Topoisomerases in therapy. Drug Resistance Updates, 1999, 2, 347-350.	14.4	2
101	Sequence-specific poisons of type II DNA topoisomerases. Advances in DNA Sequence-Specific Agents, 1998, , 7-38.	0.3	1
102	Detection of Cellular DNA Cleavage Using Non-Proofreading Thermostable DNA Polymerases. BioTechniques, 2000, 28, 1064-1066.	1.8	1
103	Abstract 637: Antisense transcripts and R-loops caused by DNA topoisomerase I inhibition by camptothecin at human active CpG island promoters.. , 2013, , .		1
104	Abstract 2143: High-Resolution Molecular Karyotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Identifies Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes. , 2010, , .		1
105	Eighth conference on DNA topoisomerases and therapy Amsterdam, The Netherlands 15â€“17 October 1997. Drug Resistance Updates, 1998, 1, 73-75.	14.4	0
106	Editorial [Hot Topic: Target Specificity of Effective Anticancer Therapeutics (Executive Editor: G.) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1	1.9	0
107	G1 Cell-Cycle Arrest and Apoptosis by Histone Deacetylase Inhibition in MLL-AF9 Acute Myeloid Leukemia Cells Is MLL-AF9 Independent.. Blood, 2005, 106, 4410-4410.	1.4	0
108	Abstract 1180: Activation of antisense transcription by Top1cc in human colon cancer cells. , 2011, , .		0

#	Article	IF	Citations
109	Transcriptional Stress by Camptothecin: Mechanisms and Implications for the Drug Antitumor Activity. Cancer Drug Discovery and Development, 2012, , 309-324.	0.4	0
110	Abstract 2243: Gene expression signature of aneuploidy in acute myeloid leukemia. , 2014, , .		0